FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316086302> ?p ?o ?g. }

• W4316086302 endingPage "e1824" @default.
• W4316086302 startingPage "e1824" @default.
• W4316086302 abstract "Introduction: Despite advancements in biologic therapy, obtaining complete remission in patients with severe stricturing Crohn’s Disease can be quite challenging. Our case highlights an unfortunate patient with severe medical-refractory Crohn’s disease who ultimately achieved clinical remission using dual immunomodulator and biologic therapy with tofacitinib and vedolizumab. Case Description/Methods: We present a 62-year-old male with a long history of ileocolonic Crohn’s disease. He was initially diagnosed in 2011 after presenting with abdominal pain. Colonoscopy at diagnosis noted ileocolonic inflammation with supportive biopsies of IBD. He was started on infliximab with improvement however this was discontinued due to financial hardships. He was transitioned to combination therapy with adalimumab and methotrexate in 2014 however his disease progressed, resulting in an SBO in 2017 requiring an ileocecectomy. He was then started on ustekinumab in 2018. Unfortunately restaging at six months noted active disease at his anastomosis. He was transitioned then to vedolizumab in 2019, however one year later was noted to have persistent inflammation at the anastomosis with stricture refractory to corticosteroids. He underwent further resection with diverting ostomy with eventual takedown in 2020 after multiple hospitalizations for high ostomy output. He was quickly restarted on vedolizumab with aggressive therapeutic drug monitoring with evidence of persistent disease activity despite the addition of methotrexate. Following a multidisciplinary discussion, his methotrexate was exchanged for tofacitinib in early 2022 with drastic improvement in both symptoms and biomarkers. Aside from a brief self-limited episode of norovirus gastroenteritis, he has tolerated dual therapy well with few adverse events. He is undergoing restaging this summer. Discussion: This case highlights the efficacy of using dual biologic and immunomodulator therapy to help treat a patient with refractory Crohn’s Disease. It is well established that combining biologics and immunomodulators can help wean steroid dependence and maintain remission in patients who suffer from IBD. While several studies have evaluated the use of tofacitinib and vedolizumab in Ulcerative Colitis, few studies have looked at rates of remission in Crohn’s Disease. This case demonstrates that the use of off-label dual biologic and immunomodulator therapy for treatment of refractory Crohn’s disease can be an effective and safe treatment for this cohort of patients." @default.
• W4316086302 created "2023-01-14" @default.
• W4316086302 creator A5042007711 @default.
• W4316086302 creator A5050829591 @default.
• W4316086302 creator A5069996084 @default.
• W4316086302 creator A5071064725 @default.
• W4316086302 creator A5083463734 @default.
• W4316086302 date "2022-10-01" @default.
• W4316086302 modified "2023-10-17" @default.
• W4316086302 title "S2785 A Case of Dual Biologic and Immunomodulator Therapy Used to Treat Refractory Crohn’s Disease" @default.
• W4316086302 doi "https://doi.org/10.14309/01.ajg.0000867780.59568.28" @default.
• W4316086302 hasPublicationYear "2022" @default.
• W4316086302 type Work @default.
• W4316086302 citedByCount "1" @default.
• W4316086302 countsByYear W43160863022023 @default.
• W4316086302 crossrefType "journal-article" @default.
• W4316086302 hasAuthorship W4316086302A5042007711 @default.
• W4316086302 hasAuthorship W4316086302A5050829591 @default.
• W4316086302 hasAuthorship W4316086302A5069996084 @default.
• W4316086302 hasAuthorship W4316086302A5071064725 @default.
• W4316086302 hasAuthorship W4316086302A5083463734 @default.
• W4316086302 hasBestOaLocation W43160863021 @default.
• W4316086302 hasConcept C121332964 @default.
• W4316086302 hasConcept C126322002 @default.
• W4316086302 hasConcept C141071460 @default.
• W4316086302 hasConcept C142424586 @default.
• W4316086302 hasConcept C197934379 @default.
• W4316086302 hasConcept C2776207728 @default.
• W4316086302 hasConcept C2777138892 @default.
• W4316086302 hasConcept C2778260677 @default.
• W4316086302 hasConcept C2778975655 @default.
• W4316086302 hasConcept C2779134260 @default.
• W4316086302 hasConcept C2779280984 @default.
• W4316086302 hasConcept C2780132546 @default.
• W4316086302 hasConcept C2781059491 @default.
• W4316086302 hasConcept C71924100 @default.
• W4316086302 hasConcept C87355193 @default.
• W4316086302 hasConceptScore W4316086302C121332964 @default.
• W4316086302 hasConceptScore W4316086302C126322002 @default.
• W4316086302 hasConceptScore W4316086302C141071460 @default.
• W4316086302 hasConceptScore W4316086302C142424586 @default.
• W4316086302 hasConceptScore W4316086302C197934379 @default.
• W4316086302 hasConceptScore W4316086302C2776207728 @default.
• W4316086302 hasConceptScore W4316086302C2777138892 @default.
• W4316086302 hasConceptScore W4316086302C2778260677 @default.
• W4316086302 hasConceptScore W4316086302C2778975655 @default.
• W4316086302 hasConceptScore W4316086302C2779134260 @default.
• W4316086302 hasConceptScore W4316086302C2779280984 @default.
• W4316086302 hasConceptScore W4316086302C2780132546 @default.
• W4316086302 hasConceptScore W4316086302C2781059491 @default.
• W4316086302 hasConceptScore W4316086302C71924100 @default.
• W4316086302 hasConceptScore W4316086302C87355193 @default.
• W4316086302 hasIssue "10S" @default.
• W4316086302 hasLocation W43160863021 @default.
• W4316086302 hasLocation W43160863022 @default.
• W4316086302 hasOpenAccess W4316086302 @default.
• W4316086302 hasPrimaryLocation W43160863021 @default.
• W4316086302 hasRelatedWork W2317479536 @default.
• W4316086302 hasRelatedWork W2326143279 @default.
• W4316086302 hasRelatedWork W2803673833 @default.
• W4316086302 hasRelatedWork W2989681206 @default.
• W4316086302 hasRelatedWork W3198548344 @default.
• W4316086302 hasRelatedWork W3207621403 @default.
• W4316086302 hasRelatedWork W4205286265 @default.
• W4316086302 hasRelatedWork W4293719479 @default.
• W4316086302 hasRelatedWork W4295254747 @default.
• W4316086302 hasRelatedWork W4353047497 @default.
• W4316086302 hasVolume "117" @default.
• W4316086302 isParatext "false" @default.
• W4316086302 isRetracted "false" @default.
• W4316086302 workType "article" @default.